Livagen
- Category
- Bioregulators
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic tetrapeptide marketed as a liver bioregulator that enters liver cells and acts on chromatin to support detox and repair. The case rests almost entirely on mechanism and animal data; claims of pain relief and digestive benefits are speculative, with essentially no human trials. No toxicology or pharmacokinetic data exist, and safety data trace mostly to one research group. Not an approved drug in the US; supply is unregulated research material.
Read Full recordStudied uses & evidence
Studied uses(4)
Chromatin remodeling and epigenetic rejuvenation
LowConsistent in cultured blood cells from older donors, but never tested in living people.
Hepatoprotection and liver function restoration
SpeculativeBased on animal and cell studies only; no human liver trials exist for this peptide.
Enkephalin preservation (endogenous pain modulation support)
SpeculativeSingle lab test showed enzyme inhibition in serum; no pain or mood studies done.
Evidence limits
- Evidence Level
- Preclinical only
All evidence comes from in vitro human cell studies and animal models. No controlled human clinical trials have been conducted or registered. Research originates almost exclusively from Khavinson's group in Russia and Georgia, with no independent Western replication.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
No formal toxicology studies meeting international regulatory standards (ICH guidelines) have been conducted.
HighSustained chromatin decondensation could theoretically increase chromosomal instability or aneuploidy risk — this has not been investigated.
TheoreticalNo pharmacokinetic data exist (absorption, distribution, metabolism, elimination are all unknown in humans).
ModerateNo reproductive or developmental toxicity assessments have been performed.
ModerateAll safety data originate exclusively from the Khavinson research network with no independent Western verification.
HighHuman oral bioavailability is unknown; laboratory findings suggest resistance to intestinal peptide hydrolysis.
ModerateNo drug interaction studies have been conducted.
ModerateLong-term effects of repeated administration are unknown.
ModerateCommercial products may vary in purity and composition; no standardized pharmaceutical quality controls apply.
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.